Severe Acute Renal Failure in Patients Treated with Glucagon-like Peptide-1 Receptor Agonists

Overview

Journal Diabetes Res Clin Pract

Specialty Endocrinology

Date 2014 Jan 23

PMID 24447807

Citations 10

Authors

D Dubois-Laforgue

D Boutboul

D J Levy

D Joly

J Timsit

Affiliations

Soon will be listed here.

Abstract

We report two patients with diabetes in whom acute renal failure requiring hemodialysis occurred while on treatment with glucagon-like peptide-1 receptor agonists. We discuss the mechanisms of this complication and the potential for its prevention.

Citing Articles

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

Guo H, Yang J, Huang J, Xu L, Lv Y, Wang Y Obes Pillars. 2025; 13:100162.

PMID: 39980735 PMC: 11840199. DOI: 10.1016/j.obpill.2025.100162.

The potential adverse effects of hypodermic glucagon-like peptide -1 receptor agonist on patients with type 2 diabetes: A population-based study.

Cheng Z, Wang S, Li F, Jin C, Mo C, Zheng J J Diabetes. 2024; 16(10):e70013.

PMID: 39435881 PMC: 11494487. DOI: 10.1111/1753-0407.70013.

Semaglutide-associated kidney injury.

Begum F, Chang K, Kapoor K, Vij R, Phadke G, Hiser W Clin Kidney J. 2024; 17(9):sfae250.

PMID: 39258261 PMC: 11384876. DOI: 10.1093/ckj/sfae250.

Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases.

Peng W, Zhou R, Sun Z, Long J, Gong Y Aging Dis. 2022; 13(2):468-490.

PMID: 35371594 PMC: 8947838. DOI: 10.14336/AD.2021.0928.

Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study.

Wang J, Huang J, Li W, Tang S, Sun J, Zhang X Br J Clin Pharmacol. 2019; 85(12):2714-2720.

PMID: 31396983 PMC: 6955414. DOI: 10.1111/bcp.14091.